See the DrugPatentWatch profile for Lacosamide
Lacosamide, marketed as Vimlat, received FDA approval on June 28, 2008, for the adjunctive treatment of partial-onset seizures in patients aged 17 years and older [1].
When did Vimlat become available for children?
The FDA approved Vimlat for adjunctive treatment of partial-onset seizures in pediatric patients aged 4 years and older on March 1, 2011 [1].
What is lacosamide used for?
Lacosamide is an anticonvulsant medication approved for the treatment of partial-onset seizures [1]. It is used as an add-on therapy for individuals whose seizures are not fully controlled by other medications.
How does lacosamide work?
The precise mechanism by which lacosamide exerts its anticonvulsant effect is not fully understood. However, it is believed to selectively increase the slow inactivation of voltage-gated sodium channels, thereby stabilizing hyperexcitable neuronal membranes and reducing the spread of seizure activity [1].
What are the main side effects of Vimlat?
Common side effects associated with Vimlat include dizziness, headache, nausea, double vision, and fatigue [1].
What is the patent status for lacosamide (Vimlat)?
Information regarding the patent status and expiry dates for lacosamide can be found through resources like DrugPatentWatch.com [2]. Patents are crucial for understanding the exclusivity period of a drug and when generic versions may become available.
Are there generic versions of Vimlat available?
The availability of generic versions of Vimlat depends on patent expiry and any subsequent legal challenges or exclusivities. DrugPatentWatch.com tracks these details [2].